Literature DB >> 2124252

Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells.

N F Go1, B E Castle, R Barrett, R Kastelein, W Dang, T R Mosmann, K W Moore, M Howard.   

Abstract

Highly purified, small dense splenic B cells from unstimulated mice showed increased expression of class II major histocompatibility complex (MHC) antigens and enhanced viability when cultured with affinity-purified recombinant interleukin 10 (rIL-10), compared with B cells cultured in medium alone. These responses were blocked by a monoclonal antibody (mAb) specific for IL-10, but not by an isotype-matched control antibody. IL-10 did not upregulate the expression of Fc epsilon receptors (CD23) or class I MHC antigens on small dense B cells or induce their replication as monitored by [3H]thymidine incorporation. While these B cell-stimulatory properties of IL-10 are also mediated by IL-4, the two cytokines appear to act independently in these assays; anti-IL-10 antibodies blocked IL-10 but not IL-4-mediated B cell viability enhancement, and vice versa. Similarly, since IL-4 upregulates CD23 on small dense B cells, the inability of IL-10 to do so argues against its acting via endogenously generated IL-4. Finally, IL-10 did not upregulate class II MHC antigens on B cells from X chromosome-linked immunodeficiency (XID) mice, while the same cells showed normal upregulation of class II antigens in response to IL-4. This report also extends our understanding of the relationship between IL-10 and the highly homologous Epstein-Barr virus (EBV)-encoded Bam HI fragment C rightward reading frame no. 1 (BCRFI) protein. It has previously been shown that BCRFI protein exhibits the cytokine synthesis inhibitory activity of IL-10. This report indicates that BCRFI protein also enhances in vitro B cell viability, but does not upregulate class II MHC antigens on B cells. One explanation for these data is that IL-10 contains at least two functional epitopes, only one of which has been conserved by EBV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124252      PMCID: PMC2188770          DOI: 10.1084/jem.172.6.1625

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor.

Authors:  R Noelle; P H Krammer; J Ohara; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 3.  CBA/N immune defective mice; evidence for the failure of a B cell subpopulation to be expressed.

Authors:  I Scher
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

Review 4.  Regulation of B-cell growth and differentiation by soluble factors.

Authors:  M Howard; W E Paul
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

5.  Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma.

Authors:  M Lotz; C D Tsoukas; S Fong; D A Carson; J H Vaughan
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

6.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1.

Authors:  J Ohara; W E Paul
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

7.  Identification of two distinct factors, B151-TRF1 and B151-TRF2, inducing differentiation of activated B cells and small resting B cells into antibody-producing cells.

Authors:  S Ono; S Hayashi; Y Takahama; K Dobashi; Y Katoh; K Nakanishi; W E Paul; T Hamaoka
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

8.  Characterization of the gamma-interferon-mediated induction of antigen-presenting ability in P388D1 cells.

Authors:  A Zlotnik; R P Shimonkevitz; M L Gefter; J Kappler; P Marrack
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

9.  Interleukin-induced increase in Ia expression by normal mouse B cells.

Authors:  N W Roehm; H J Leibson; A Zlotnik; J Kappler; P Marrack; J C Cambier
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

10.  Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation.

Authors:  F Hasler; H G Bluestein; N J Zvaifler; L B Epstein
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  138 in total

1.  Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10).

Authors:  S V Kotenko; S Saccani; L S Izotova; O V Mirochnitchenko; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Calorie restriction decreases proinflammatory cytokines and polymeric Ig receptor expression in the submandibular glands of autoimmune prone (NZB x NZW)F1 mice.

Authors:  A R Muthukumar; C A Jolly; K Zaman; G Fernandes
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 4.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

5.  HLA-DRB1 gene transcripts in rheumatoid arthritis.

Authors:  S Kerlan-Candon; B Combe; R Vincent; J Clot; V Pinet; J F Eliaou
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

6.  Various types of Dirofilaria immitis polyproteins selectively induce a Th2-Type immune response.

Authors:  Hiroyuki Tezuka; Shinjiro Imai; Shinya Hidano; Setsuko Tsukidate; Koichiro Fujita
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 7.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 8.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

9.  In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies.

Authors:  S Nisitani; R M Kato; D J Rawlings; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

10.  Production of interleukin-10 by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; M D Burdick; C A Wilke; M B Orringer; R I Whyte; R M Strieter
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.